Xencor(XNCR)

Focus: Xencor is a public biotechnology company headquartered in Pasadena specializing in antibody discovery with a focus on oncology and immunology therapeutics. The company operates as a mid-cap biotech with $175M in FY2025 revenue and an expansive pipeline of 32 clinical programs.

Oncology Immunology

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Xencor

AI assessmentNot Hiring

No open roles listed right now. Follow Xencor to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Early-stage

33 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$175M

Pipeline & Clinical Trials

XmAb®23104

Melanoma (Excluding Uveal Melanoma)

PHASE_1

Clinical Trials (1)

NCT03752398A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

Phase 1

Help build intelligence for Xencor

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Deep antibody engineering expertise — core competency in XmAb platform technology across 32 active programs spanning oncology and immunology
Broad pipeline diversity — 10 Phase 2 programs (Plamotamab, Vudalimab, XmAb5871) provide multiple near-term clinical catalysts and career visibility
Public company stability — NASDAQ-listed with $41M cash runway and growing revenue ($165M→$175M YoY) supporting R&D expansion

Watch Out For

No marketed products — zero revenue from proprietary therapeutics; entirely dependent on partnership revenue and milestone income, creating execution risk
Significant cash burn — $254M R&D spend on $175M revenue (145% intensity) with $133M net loss (FY2025) means limited runway despite public funding
Early-stage pipeline concentration — 25 of 32 programs in Phase 1; no Phase 3 programs limits near-term commercialization optionality and job security

Generated by Claude from Xencor's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

XmAb13676

Healthy

PHASE_1

Clinical Trials (1)

NCT07284797A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Idiopathic Inflammatory Myopathy (IIM)

Phase 1

XmAb7195

Healthy Volunteers

PHASE_1

Clinical Trials (1)

NCT02881853Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195

Phase 1

AMG 424

Relapsed/ Refractory Multiple Myeloma

PHASE_1

Clinical Trials (1)

NCT03445663Study Evaluating AMG 424 in Subjects With Multiple Myeloma

Phase 1

XmAb14045

Acute Myelogenous Leukemia

PHASE_1

Clinical Trials (1)

NCT02730312PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies

Phase 1

XmAb819

Clear Cell Renal Cell Carcinoma

PHASE_1

Clinical Trials (1)

NCT05433142Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

Phase 1

XmAb13676

Rheumatoid Arthritis

PHASE_1

Clinical Trials (1)

NCT07230353A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis

Phase 1

XmAb5574

Chronic Lymphocytic Leukemia

PHASE_1

Clinical Trials (1)

NCT01161511Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia

Phase 1

XmAb27564

Psoriasis

PHASE_1

Clinical Trials (1)

NCT06005792Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis

Phase 1

XmAb22841

Metastatic Melanoma

PHASE_1

Clinical Trials (1)

NCT05695898XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy

Phase 1

XmAb®808

Head and Neck Squamous Cell Carcinoma

PHASE_1

Clinical Trials (1)

NCT05585034Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

Phase 1

XmAb7195

Allergic Rhinitis

PHASE_1

Clinical Trials (1)

NCT02148744Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis

Phase 1

XmAb2513

Hodgkin Lymphoma

PHASE_1

Clinical Trials (1)

NCT00606645Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma

Phase 1

XmAb18087

Neuroendocrine Tumor

PHASE_1

Clinical Trials (1)

NCT03411915A Study of XmAb®18087 in Subjects With NET and GIST

Phase 1

XmAb27564

Safety in Healthy Volunteers

PHASE_1

Clinical Trials (1)

NCT04857866Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy Volunteers

Phase 1

XmAb5871

Healthy Volunteers

PHASE_1

Clinical Trials (1)

NCT02867098XmAb5871 Bioavailability Study

Phase 1

XmAb662

Solid Tumors

PHASE_1

Clinical Trials (1)

NCT05996445A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors

Phase 1

Abiraterone

Castration-Sensitive Prostate Carcinoma

PHASE_1

Clinical Trials (1)

NCT05733351Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

Phase 1

XmAb13676

B-cell Non-Hodgkins Lymphoma

PHASE_1

Clinical Trials (1)

NCT02924402Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

Phase 1

XmAb541

Ovarian Cancer

PHASE_1

Clinical Trials (1)

NCT06276491Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

Phase 1

XmAb®22841

Melanoma

PHASE_1

Clinical Trials (1)

NCT03849469A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Phase 1

XmAb20717

Melanoma

PHASE_1

Clinical Trials (1)

NCT03517488A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

Phase 1

Vudalimab + Carboplatin + Pemetrexed

Nonsquamous Non-small Cell Lung Cancer

PHASE_1_2

Clinical Trials (1)

NCT06173505Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC

Phase 1/2

XmAb18087

Merkel Cell Carcinoma

PHASE_1_2

Clinical Trials (1)

NCT04590781Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer

Phase 1/2

XmAb942

Ulcerative Colitis (UC)

PHASE_1_2

Clinical Trials (1)

NCT06619990Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

Phase 1/2

XmAb23104

Sarcoma

PHASE_2

Clinical Trials (1)

NCT05879185A Study of XmAb23104 in People With Sarcoma

Phase 2

XmAb5871

Systemic Lupus Erythematosus

PHASE_2

Clinical Trials (1)

NCT02725515A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus

Phase 2

vudalimab + carboplatin + cabazitaxel

Metastatic Castration-Resistant Prostate Cancer

PHASE_2

Clinical Trials (1)

NCT05005728XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2

XmAb5871

IgG4-RD

PHASE_2

Clinical Trials (1)

NCT02725476Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)

Phase 2

XmAb20717

Biliary Tract Cancer

PHASE_2

Clinical Trials (1)

NCT05297903XmAb20717 in Advanced Biliary Tract Cancers

Phase 2

Plamotamab

Diffuse Large-cell B-cell Lymphoma

PHASE_2

Clinical Trials (1)

NCT05328102Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)

Phase 2

Regorafenib

Colorectal Cancer

PHASE_2

vudalimab

Ovarian Cancer

PHASE_2

Clinical Trials (1)

NCT05032040A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 32 clinical trials

Top TAs: Oncology, Immunology

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

22 pipeline

Immunology

5 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$175M6%

R&D Spend

$254M(145%)27%

Net Income

-$133M

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles